shares surged 38% in its trading debut, after the heart-health focused biotech raised $400 million in an initial public offering. The company’s shares closed at $22, above its IPO price of $16. The trading gives Kardigan a market value of nearly $2 billion, based on the outstanding shares. The heart-health focused biotech sold 25 million shares at $16 each, according to a Wednesday. The firm had marketed 23.3 million shares for $14 to $16 each, an earlier filing showed.